See more : Angkor Resources Corp. (ANK.V) Income Statement Analysis – Financial Results
Complete financial analysis of Connect Biopharma Holdings Limited (CNTB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Connect Biopharma Holdings Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Ault Disruptive Technologies Corporation (ADRT-UN) Income Statement Analysis – Financial Results
- Buffalo Coal Corp. (BUC.JO) Income Statement Analysis – Financial Results
- PowerSchool Holdings, Inc. (PWSC) Income Statement Analysis – Financial Results
- TruBridge, Inc. (TBRG) Income Statement Analysis – Financial Results
- Barrick Gold Corporation (GOLD) Income Statement Analysis – Financial Results
Connect Biopharma Holdings Limited (CNTB)
About Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 988.00K | 1.03M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -988.00K | -1.03M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 51.91M | 95.26M | 81.34M | 23.12M | 15.44M |
| General & Administrative | 14.52K | 20.37M | 19.23M | 7.31M | 1.41M |
| Selling & Marketing | 13.51M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.53M | 20.37M | 19.23M | 7.31M | 1.41M |
| Other Expenses | -4.35M | -940.31K | -2.98M | -1.07M | -411.44K |
| Operating Expenses | 62.07M | 114.69M | 97.59M | 29.36M | 16.44M |
| Cost & Expenses | 62.07M | 114.69M | 97.59M | 29.36M | 16.44M |
| Interest Income | 5.20K | 1.56M | 97.67K | 109.84K | 154.65K |
| Interest Expense | 0.00 | 21.03K | 6.91K | 6.43K | 7.69K |
| Depreciation & Amortization | 988.00K | 1.01M | 640.98K | 221.05K | 114.61K |
| EBITDA | -58.37M | -111.31M | -204.93M | -118.21M | -24.78M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -62.07M | -117.66M | -99.15M | -30.30M | -15.99M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.69M | -403.66K | -103.21M | -89.07M | -8.41M |
| Income Before Tax | -59.38M | -116.12M | -204.94M | -119.37M | -24.46M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 120.00K | 297.52K | 266.47K | 934.46K | -442.49K |
| Net Income | -59.50M | -116.42M | -205.21M | -120.30M | -24.02M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.08 | -14.50 | -25.00 | -14.45 | -3.02 |
| EPS Diluted | -1.08 | -14.50 | -25.00 | -14.45 | -3.02 |
| Weighted Avg Shares Out | 55.07M | 55.04M | 52.27M | 53.94M | 55.82M |
| Weighted Avg Shares Out (Dil) | 55.07M | 55.04M | 52.27M | 53.94M | 55.82M |
Connect Biopharma to Present at the San Francisco Biotech Showcase in January
Connect Biopharma To Present at Upcoming Investor and Scientific Conferences
Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis
Connect Biopharma Is A Sleeper Heading Into October Data Readout
Connect Biopharma Holdings Limited (CNTB) Q2 2022 Earnings Call Transcript
Connect Biopharma to Report First Half 2022 Financial Results on September 13
Hot Penny Stocks That Are Climbing Right Now
All You Need to Know About Connect Biopharma Holdings Limited Sponsored ADR (CNTB) Rating Upgrade to Buy
Connect Biopharma Stock Plunges As Ulcerative Colitis Candidate Flunks In Mid-Stage Study
Connect Biopharma to Participate at the SVB Leerink 11th Annual Global Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports